DBIA
AGRX

Dumont & Blake Investment Advisors’s Agile Therapeutics AGRX Stock Holding History

Dumont & Blake Investment Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-35
Closed -$67K – 210
2021
Q3 		$67K Sell
35
-20
-36% -$45.3K 0.02% 199
2021
Q2 		$146K Buy
55
+5
+10% +$16.5K 0.04% 198
2021
Q1 		$208K Hold
50
– – 0.06% 190
2020
Q4 		$287K Hold
50
– – 0.1% 157
2020
Q3 		$304K Buy
50
+7
+16% +$40.1K 0.12% 140
2020
Q2 		$239K Buy
43
+12
+39% +$62.4K 0.1% 153
2020
Q1 		$113K Buy
+31
New +$178K 0.06% 157

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dumont & Blake Investment Advisors's AGRX Position: Q4 2021 in Review

Dumont & Blake Investment Advisors sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 35 shares — an estimated $67K sold.

Dumont & Blake Investment Advisors first reported a position in AGRX in Q1 2020 and held it in 7 quarters. The position peaked at $304K in Q3 2020. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

  • Dumont & Blake Investment Advisors reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Dumont & Blake Investment Advisors sold 35 Agile Therapeutics shares in Q4 2021, an estimated $67K.
  • Dumont & Blake Investment Advisors first reported a position in Agile Therapeutics in Q1 2020 and held it in 7 quarters.
  • Dumont & Blake Investment Advisors's Agile Therapeutics position peaked at $304K in Q3 2020.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on Dumont & Blake Investment Advisors's 13F filing for Q4 2021, filed 31 Jan 2022.